Melior Discovery

Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist

Retrieved on: 
Monday, September 19, 2022
Central nervous system, CFO, Safety, Movement, Sirna, DuPont, Psychiatry, FAP, NASH, Rouge, OTCQB, Company, Senior, ATRX, Private Securities Litigation Reform Act, Melior Discovery, Therapy, Forward-looking statement, U.S. Securities and Exchange Commission, GlaxoSmithKline, Patient, Risk, Type 1 diabetes, CEO, Drug development, Fatty liver disease, Board, RNA, Research, Security (finance), GLOBE, Corporate development, Communication, Sanofi, Management, Pharmaceutical industry

Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways.

Key Points: 
  • Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways.
  • Adhera is developing MLR-1023 (tolimidone) as a new drug for Type I diabetes with a focus on C-peptide positive patients.
  • Adhera Therapeutics has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions.
  • A more complete description of these risk factors is included in Adhera Therapeutics filings with the Securities and Exchange Commission.

Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin

Retrieved on: 
Tuesday, July 19, 2022
NASH, Research, RNA, OTCQB, Cancer, Patient, Central nervous system, Iron, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Large-cell lung carcinoma, TFR1, Security (finance), Transferrin, Paclitaxel, U.S. Securities and Exchange Commission, Fatty liver disease, Safety, Sirna, Therapy, Type 1 diabetes, FAP, GLOBE, Private Securities Litigation Reform Act, Food, Transferrin receptor 1, Forward-looking statement, ATRX, Risk, Psychiatry, Melior Discovery, Drug development, Company, Hypercalcaemia, Lung cancer, Rouge, Breast, Malignancy, Gallium, FDA, CD71, PGT, Movement, Pharmaceutical industry

PGT is designed to deliver paclitaxel to cancer cells over-expressing Transferrin Receptor 1, also known as CD71 or TFR1.

Key Points: 
  • PGT is designed to deliver paclitaxel to cancer cells over-expressing Transferrin Receptor 1, also known as CD71 or TFR1.
  • Sb-paclitaxel is approved for breast, ovarian, and lung cancer and Kaposis Sarcoma, while nab-paclitaxel is approved for breast, pancreatic, and non-small cell lung cancer.
  • Gallium nitrate (brand name GANITE) is FDA-approved for hypercalcemia of malignancy, a common finding in patients with advanced stage cancer.
  • A more complete description of these risk factors is included in Adhera Therapeutics filings with the Securities and Exchange Commission.

Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ

Retrieved on: 
Thursday, May 19, 2022
Business, API, Company, Disease, Type 1, Private Securities Litigation Reform Act, Royal Norwegian Society for Development, U.S. Securities and Exchange Commission, NASH, CSO, Rouge, BD, Lundy–Fetterman School of Business, Patient, NASDAQ, Fatty liver disease, Type 1 diabetes, Psychiatry, Therapy, School, Campbell University, ATRX, Marketing, Novartis, M&A, BS, Research, Time, FAP, Forward-looking statement, RNA, Central nervous system, Safety, Risk, Melior Discovery, Drug development, Dyskinesia, Security (finance), Movement, Sirna, OTCQB, GLOBE, Pharmaceutical industry, Management

In the last six years, Mr. Waerness has founded/co-founded three successful and profitable pharma services companies.

Key Points: 
  • In the last six years, Mr. Waerness has founded/co-founded three successful and profitable pharma services companies.
  • Mr. Waerness is assuming the role of Chairman, replacing Andrew Kucharchuk, who will remain Chief Executive Officer and Vice-Chairman.
  • Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways.
  • A more complete description of these risk factors is included in Adhera Therapeutics filings with the Securities and Exchange Commission.

Melior Announces Substantial Additions to Its Management and Scientific Team

Retrieved on: 
Tuesday, April 12, 2022
Pharmaceutical, Health, Oncology, Foundation for the National Institutes of Health, CEO, Pain, Lists of diseases, LLC, MBA, Doctor of Philosophy, Pfizer, Inflammation, Hospital, GlaxoSmithKline, Research and development, Environment, Research associate, Hospital for Sick Children (Toronto), National Institute, PDX, Toronto, Neurodegeneration, Melior Discovery, Knowledge, Management, Pharmaceutical industry, Oncology, Pharmacology, Melior, Research

Melior Discovery, Inc. (Melior) announced today significant additions to its management organization.

Key Points: 
  • Melior Discovery, Inc. (Melior) announced today significant additions to its management organization.
  • Joining the Melior organization will be Dr. Ken Kilgore (PhD, MBA) as Vice President of Pharmacology.
  • In addition, Melior veteran, Dr. Vivian Cong, will rise to the role of Vice President of Research and Development.
  • Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA. For more information, visit www.meliordiscovery.com and www.meliorpharma.com .

Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace

Retrieved on: 
Thursday, January 20, 2022
U.S. Securities and Exchange Commission, Forward-looking statement, Patient, Research, Central nervous system, Melior Discovery, Private Securities Litigation Reform Act, OTCQB, RNA, Safety, Fatty liver disease, ATRX, GLOBE, Sirna, Movement, NASH, Type 1 diabetes, Therapy, Company, FAP, Drug development, PD, Rouge, Psychiatry, Compliance, Security (finance), Risk, Pharmaceutical industry

Baton Rouge, LA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce its successful uplisting from the OTC Pink Sheets to the OTCQB Venture Marketplace (the OTCQB).

Key Points: 
  • Baton Rouge, LA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce its successful uplisting from the OTC Pink Sheets to the OTCQB Venture Marketplace (the OTCQB).
  • Adhera will commence trading on the OTCQB at the market open on January 20, 2022 under the ticker ATRX.
  • Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways.
  • A more complete description of these risk factors is included in Adhera Therapeutics filings with the Securities and Exchange Commission.

Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders

Retrieved on: 
Monday, November 22, 2021
Patient, Movement, Canadian Intellectual Property Office, PD, Investigational New Drug, Company, Rouge, ATRX, Melior Discovery, IND, Melior, Central nervous system, Psychiatry, Sirna, GLOBE, LLC, Patent, RNA, NASH, FAP, Therapy, Type 1 diabetes, Drug development, Fatty liver disease, Pharmaceutical industry

Melior has received a Notice of Allowance from the Canadian Intellectual Property Office for the patent, titled, Methods of Treating Dyskinesia and Related Disorders.

Key Points: 
  • Melior has received a Notice of Allowance from the Canadian Intellectual Property Office for the patent, titled, Methods of Treating Dyskinesia and Related Disorders.
  • Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various psychiatric and central nervous system indications.
  • Adhera is developing MLR-1023 (tolimidone) as a new drug for Type I diabetes with a focus on C-peptide positive patients.
  • Adhera also has exclusive rights to develop MLR-1023 for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation diseases and conditions.

Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications

Retrieved on: 
Wednesday, October 20, 2021
Fatty liver disease, Liver, Immune system, Risk, Degenerative disease, Yolk sac, Contributor License Agreement, Mortal Kombat, Death, FAP, License, Private Securities Litigation Reform Act, COVID-19, NASH, PD, Melior Discovery, U.S. Securities and Exchange Commission, Pulmonary edema, Sirna, Growth hacking, Diabetes, Security (finance), Drug development, RNA, Coronavirus, Disease, Central nervous system, Severe acute respiratory syndrome, Melior, Pharmacology, Research, Sepsis, Infection, Vaccine, Therapy, Safety, Psychiatry, Patient, LLC, Forward-looking statement, SARS, Type 1 diabetes, Cytokine, Lists of diseases, Company, Movement, Pharmaceutical industry

NASH is also a metabolic disease where, much like diabetes, lyn kinase expression could be an ideal pathway to developing next-generation treatments.

Key Points: 
  • NASH is also a metabolic disease where, much like diabetes, lyn kinase expression could be an ideal pathway to developing next-generation treatments.
  • Regarding pulmonary edema, MLR-1023 is clearly differentiated from commonly used therapeutics today, including anti-inflammatory drugs and vaccines.
  • Adhera also has exclusive rights to develop MLR-1023 for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation diseases and conditions.
  • Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA. For more information, visit www.meliordiscovery.com and www.Meliorpharmaceuticals.com .

Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s Disease

Retrieved on: 
Friday, October 15, 2021
Risk, Korean Intellectual Property Office, Central nervous system, History, Sirna, Private Securities Litigation Reform Act, Publication, Type 1 diabetes, IND, End-user license agreement, ATRX, Korean, Security (finance), PD, Lists of diseases, License, Dyskinesia, Disease, Movement, RNA, FAP, Patient, L-DOPA, GLOBE, U.S. Securities and Exchange Commission, Forward-looking statement, Company, Drug development, Psychiatry, Safety, Patent, Therapy, Research, Rouge, Melior Discovery, Investigational New Drug, Pharmaceutical industry

Baton Rouge, LA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that manufacturing has commenced of MLR-1019 (armesocarb) for use in the Company’s planned Phase 2a clinical trial as a new therapeutic for Parkinson’s disease (PD). Adhera is also pleased to inform shareholders that a new patent has been issued covering MLR-1019 in Korea.

Key Points: 
  • To the best of the Companys knowledge, all existing agents that treat movement disorder, exacerbate non-movement disorder features of PD.
  • Enrollment in the Phase 2 trial is expected to consist of Parkinsons disease patients with L-DOPA induced dyskinesia, a commonly seen and potentially disabling movement side effect of treating PD with levodopa.
  • Product manufacturing is a milestone for us as we move closer to initiating what we believe could be a landmark study in Parkinsons disease treatments, commented Andrew Kucharchuk, Chief Executive Officer at Adhera Therapeutics.
  • MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies.

Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias

Retrieved on: 
Monday, October 4, 2021
Melior, Patent, End-user license agreement, Therapy, European Patent Convention, RNA, Risk, Security (finance), Investigational New Drug, License, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Melior Discovery, Patient, FAP, Central nervous system, Writing, GLOBE, Company, Sirna, LLC, Eating, PD, Embarrassment, ATRX, IND, Research, Psychiatry, Drug development, Safety, Forward-looking statement, Intellectual property, Movement, Rouge, Type 1 diabetes, European Patent Office, Pharmaceutical industry

Melior has received notice from the European Patent Office that the patent, titled, Methods of Treating Dyskinesia and Related Disorders, passed the required period without any opposition being filed, triggering the issuance of the patent.

Key Points: 
  • Melior has received notice from the European Patent Office that the patent, titled, Methods of Treating Dyskinesia and Related Disorders, passed the required period without any opposition being filed, triggering the issuance of the patent.
  • Given that our development plans for MLR-1019 begin in Eastern Europe, the new patent is particularly timely as part of a robust patent portfolio protecting the intellectual property, commented Andrew Kucharchuk, Chief Executive Officer at Adhera Therapeutics.
  • Dyskinesias have a negative impact both functionally and socially on most Parkinsons patients, causing embarrassment while inhibiting their ability for daily tasks, including writing, dressing, and eating.
  • A more complete description of these risk factors is included in Adhera Therapeutics filings with the Securities and Exchange Commission.

Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs

Retrieved on: 
Monday, September 13, 2021
Risk, Type 1, U.S. Securities and Exchange Commission, Movement, Therapy, Melior Discovery, Security (finance), Central nervous system, CEO, Sirna, University, Drug development, Forward-looking statement, PD, Doctor of Philosophy, Patient, NPV, Company, Private Securities Litigation Reform Act, Drug repositioning, LLC, Type 2, Type 1 diabetes, Genetics, FAP, IND, ATRX, Entrepreneurship, Safety, NASDAQ, Rouge, Investigational New Drug, License, RNA, Type 2 diabetes, MBA, Psychiatry, GLOBE, OTC, Melior, Contributor License Agreement, Research, Wendell Pritchett, Wharton School of the University of Pennsylvania, Pharmaceutical industry

On July 29, 2021 and August 24, 2021 , respectively, the Company announced executing exclusive license agreements for MLR-1019 for Parkinsons disease (PD) and MLR-1023 for Type 1 diabetes.

Key Points: 
  • On July 29, 2021 and August 24, 2021 , respectively, the Company announced executing exclusive license agreements for MLR-1019 for Parkinsons disease (PD) and MLR-1023 for Type 1 diabetes.
  • Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways.
  • Adhera is developing MLR-1023 (tolimidone) as a new drug for Type I diabetes with a focus on C-peptide positive patients.
  • A more complete description of these risk factors is included in Adhera Therapeutics filings with the Securities and Exchange Commission.